Pulmonary Function in Non-hospitalized Adults and Children After Mild COVID-19

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06318208

Enrollment

110

Registered

2024-03-19

Start date

2021-04-20

Completion date

2022-01-03

Last updated

2024-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV-2 Infection

Keywords

mild COVID-19, LCI, lung function, non-hospitalized COVID-19

Brief summary

The study investigates whether patients with mild SARS-CoV-2 infection, who stayed at home during their infection and weren't hospitalized, have any persisting sequelae in pulmonary function. Therefore, 110 patients, aged 6-60 years, were recruited by telephone 4-12 weeks after laboratory-confirmed positive PCR and invited for a lung function testing. Every patient with abnormalities in pulmonary function was invited to a follow-up 3 months after the first appointment to assess changes in lung function values. Patients with a pre-existing lung disease and smokers within the last five years were excluded beforehand. Additionally to lung function testing we did a throat swab at each appointment to analyse via Multiplex PCR whether the patients had any other respiratory infection at the time of the pulmonary function testing.

Detailed description

110 patients, 90 adults and 20 children, were recruited. The lung function included LCI, FEV1, FVC and DLCO (Hb corrected). Additionally we did a throat swab at each appointment to analyse via Multiplex PCR whether the patients had any other respiratory infection at the time of the test.

Interventions

DIAGNOSTIC_TESTlung function testing

lung function testing including LCI, FEV1, FVC, DLCO

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

6 Years to 60 Years

Healthy volunteers

Inclusion criteria

* SARS-CoV-2 Infection, non-hospitalized during infection

Exclusion criteria

* Smoking, existing lung disease (COPD, Asthma bronchiale)

Design outcomes

Primary

Measure	Time frame	Description
Pulmonary function	4.3 - 11.3 weeks after positive PCR for SARS-CoV-2	Pulmonary function after SARS-CoV-2 Infection

Secondary

Measure	Time frame	Description
Changes in pulmonary function	11.0 - 16.7 weeks after the first lung function testing	Changes in pulmonary function towards the follow-up
Sociodemographic factors	9 months	Relation of pulmonary function to sociodemographic factors

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026